Alveoli
发表于 2025-3-25 07:04:04
http://reply.papertrans.cn/23/2264/226396/226396_21.png
影响深远
发表于 2025-3-25 10:43:44
http://reply.papertrans.cn/23/2264/226396/226396_22.png
一起
发表于 2025-3-25 12:16:27
http://reply.papertrans.cn/23/2264/226396/226396_23.png
Original
发表于 2025-3-25 16:43:04
https://doi.org/10.1007/978-3-030-34898-4n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
方舟
发表于 2025-3-25 22:12:24
Franz Breuer,Petra Muckel,Barbara Dierisbe recommended for patients with a well matched donor and low risk transplant profile as early as possible. It is discouraged for patients with failed response to multiple TKIs and no matched donor. Close interaction between CML physicians and transplant centers facilitates such a targeted risk adapted approach.
发酵剂
发表于 2025-3-26 01:20:34
,Gütekriterien und ethische Fragen,ost importance even for drug companies. It should be considered the future criterion to evaluate the success of clinical trials, especially if we want to take into account quality of life of patients and also the economic aspect..The question of cure in CML is now one of the major concerns and has to be considered in the management of the disease.
分期付款
发表于 2025-3-26 04:29:39
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia,n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
发出眩目光芒
发表于 2025-3-26 09:34:53
http://reply.papertrans.cn/23/2264/226396/226396_28.png
Connotation
发表于 2025-3-26 15:38:21
http://reply.papertrans.cn/23/2264/226396/226396_29.png
决定性
发表于 2025-3-26 18:54:50
Response-Related Predictors of Survival in CML,h of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI, and for second-line TKI treatment as well.